Dermata Therapeutics, Inc.
$1.34
▲
7.5%
2026-04-21 06:29:00
www.dermatarx.com
NCM: DRMA
Explore Dermata Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.47 M
Current Price
$1.34
52W High / Low
$9.9 / $1.1
Stock P/E
—
Book Value
$2.34
Dividend Yield
—
ROCE
-124.91%
ROE
-1.94%
Face Value
—
EPS
$-8.16
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
0.5
Debt / Equity
—
Current Ratio
4.79
Quick Ratio
4.79
Forward P/E
-0.32
Price / Sales
—
Enterprise Value
$-2.61 M
EV / EBITDA
—
EV / Revenue
—
Rating
Buy
Target Price
$4
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aptevo Therapeutics Inc. | $5.21 | — | $6.24 M | — | -124.44% | -2.35% | $486 / $3.8 | $17.42 |
| 2. | Ionis Pharmaceuticals, Inc. | $74.84 | — | $12.38 B | — | -13.92% | -70.8% | $86.74 / $27.9 | $3 |
| 3. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 4. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 5. | Veradermics, Incorporated | $73.97 | — | $2.85 B | — | -49.88% | -72.06% | $80.9 / $32 | $-131.48 |
| 6. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 7. | Corvus Pharmaceuticals, Inc. | $15.54 | — | $1.31 B | — | -69.6% | -32.6% | $26.95 / $3.11 | $0.82 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.9 M | -1.76 M | -1.77 M | -2.34 M | -3.2 M | — |
| Net Profit | -1.86 M | -1.69 M | -1.7 M | -2.3 M | -3.15 M | — |
| EPS in Rs | -0.46 | -0.42 | -0.42 | -0.57 | -0.78 | -20.41 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -7.77 M | -12.51 M | -8.04 M | -9.67 M |
| Net Profit | -7.56 M | -12.29 M | -7.79 M | -9.61 M |
| EPS in Rs | -1.88 | -3.05 | -1.94 | -2.39 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.86 M | 3.53 M | 7.98 M | 6.94 M |
| Total Liabilities | 1.64 M | 1.97 M | 1.62 M | 0.92 M |
| Equity | 6.22 M | 1.56 M | 6.36 M | 6.02 M |
| Current Assets | 7.86 M | 3.53 M | 7.98 M | 6.94 M |
| Current Liabilities | 1.64 M | 1.97 M | 1.62 M | 0.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.76 M | -11.16 M | -6.41 M | -8.83 M |
| Investing CF | — | — | — | — |
| Financing CF | 12.12 M | 6.89 M | 7.61 M | 4.28 M |
| Free CF | -7.76 M | -11.16 M | -6.41 M | -8.83 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -57.64% | 18.9% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-01 | 1:0.1 |
| 2024-05-16 | 1:0.0666667 |
| 2023-03-14 | 1:0.0625 |